New production processes promise to lower cost of biopharmaceuticals

New production processes promise to lower cost of biopharmaceuticals

Drugs derived from biological sources play a major role in modern healthcare, but producing them cost-effectively to keep up with rising demand is a major challenge for the pharmaceutical industry. EU-funded researchers are developing more efficient biopharmaceutical manufacturing processes that should expand patients' access to these highly effective therapies.
Date: 
22/12/2016 - 12:47

Biopharmaceuticals have been used against many health conditions since biosynthetic human insulin was first approved as a therapy for diabetes in 1982.

Developed using recombinant DNA (rDNA) technology to produce molecules with novel genetic traits, bio-drugs are usually divided into different subgroups: substances that are virtually identical to the body’s own key signalling proteins such as the hormones insulin and erythropoietin; monoclonal antibodies with the same structure as the body’s own antibodies produced by immune cells; and fusion proteins formed from two or more genes. All play essential roles in modern medicine, often as treatments for life-threatening and disabling diseases such as cancer, diabetes or rheumatoid arthritis.

Read more

nextBioPharmDSP
See also: 
Project details
Project: 
Next-generation biopharmaceutical downstream process
Image of scientist's hand putting leaves into petri dishes
© Robert Przybysz - fotolia.com
Rapid Press Release: 
Do Not Publish as Rapid Press Release
Contact
Source: 
http://ec.europa.eu/programmes/horizon2020/en/news/new-production-processes-promise-lower-cost-biopharmaceuticals

Share this post

Author